The MassGeneral Institute for Neurodegenerative Disease (MIND) was established in 2001 to accelerate research discoveries that will lead to treatment and cures for memory, movement, and neuromuscular disorders.

Leadership

The institute was founded by and is directed by Anne B. Young, MD, PhD, formerly Chief of Neurology and Julianne Dorn Professor of Neurology at Harvard Medical School. Laboratories are directed by MD’s, PhD’s and MD/PhD’s who are members of the faculty of Harvard Medical School and have appointments in the Mass General departments of Neurology, Neurosurgery, Psychiatry, and Pathology.

In this uniquely integrated research center, a team of world-renowned experts together with young, innovative researchers collaborate, strategize, and share technology to find treatment for these diseases. As promising leads are developed in one area, they are tested in the other neurodegenerative disorders.

Since many of the laboratories at MIND are led by physician-scientists, translating scientific breakthroughs into drugs and other therapies that will improve the lives of patients is MIND’s core mission.

The MassGeneral Institute for Neurodegenerative Disease’s model of collaboration and sharing of resources will hasten the pace of discovery and, we hope, change the prognosis for these diseases in this generation.

MassGeneral Institute for Neurodegenerative Disease was founded in 2001 with a mission to translate laboratory discoveries into prevention, treatment and cures for Alzheimer’s, ALS, Huntington’s, Parkinson’s and other neurodegenerative diseases. Driven by a sense of urgency due to our nation’s burgeoning aging population, MIND seeks to accelerate therapies that lessen the devastating toll of disease on patients and families.

While the symptoms differ, Alzheimer’s, Parkinson’s, ALS and Huntington’s diseases have characteristics that point to related mechanisms. We can now see that advances in one disease are likely to hold promise for the other disorders. MIND is poised to take advantage of this synergy by encouraging researchers to collaborate, communicate, take risks, and defy conventional thinking.

Infrastructure

  • Broadest range of neurodegenerative disease research in the world–from basic research to clinical trial design–consisting of over a dozen different laboratories with more than 125 scientists, physicians, technical staff and fellows.
  • Exceptionally talented researchers who have made outstanding contributions to their fields, joined by rising stars in neuroscience.
  • Multifaceted, collaborative research approach engaging both physicians and scientists.
  • Integrated research effort that seeks opportunities for cross-fertilization of ideas and approaches among different diseases.
  • Innovative drug discovery efforts geared to slow or stop progression of diseases – the first high throughput drug screening program in an academic medical center.
  • Access to the broad clinical trial capabilities of the MassGeneral to ensure rapid deployment of potential new drugs.
  • State-of-the-art facility designed to foster creativity and teamwork with open laboratories, shared technology and vibrant intellectual life.
  • Equipment and resources that are essential for translational research: high-tech microscopes, gene sequencing machines, a human brain bank, drug screening robotics, and a laboratory for testing new disease-fighting strategies in mice.
  • International collaborations to disseminate findings and incorporate new approaches.

 

© 2011 MassGeneral Institute for Neurodegenerative Disease

patient

RSVP for Health

Enroll in RSVP for Health, Mass General's Research Study Volunteer Program, to receive information about new clinical research studies related to your medical condition.

patient

Services for the media

The public affairs team is available around the clock to handle interview and information requests or to connect the media with subject matter experts.